aibioAlector to cut workforce by approximately 13%, expects $2.4 million in restructuring charges
Tickers ALEC
The company says the cut affects about 25 employees and will cost about $2.4 million. It still says cash lasts through 2026, while its lead frontotemporal dementia trial has yet to report and its term loan is secured on substantially all assets.
Key facts
- Company
- Alector, Inc. (NASDAQ: ALEC)
- News type
- Distress
- Primary source
- Alector, Inc. Form 8-K filed March 10, 2025 (SEC EDGAR)
Alector, Inc. (Nasdaq: ALEC) said it will cut its workforce by approximately 13% and expects one-time restructuring charges of approximately $2.4 million. The company disclosed the plan in a Form 8-K filed March 10, 2025 under Item 2.05, the item for costs tied to exit or disposal activities. The filing also says Alector still expects its cash to fund operations through 2026.
What the filing says
Alector committed on March 7, 2025 to a plan to reduce its workforce by approximately 13%. The company calls it part of its cost reduction initiatives, meant to align resources with its strategic priorities, including advancing its preclinical and research pipeline. The reduction in force has been initiated and affects approximately 25 employees across the organization.
Alector expects one-time restructuring charges of approximately $2.4 million, made up primarily of personnel expenses such as salaries, one-time severance payments and other benefits. It expects the cash payments to be made, and the reduction to be completed, during the third quarter of 2025. The 8-K warns that the costs are subject to a number of assumptions, that actual results may differ significantly, and that the company may incur additional costs not currently contemplated. Chief Financial Officer Marc Grasso, M.D. signed the filing.
The company says it continues to expect that its existing cash, cash equivalents and investments will fund operating expenses and capital expenditure requirements through 2026. The 8-K gives no cash balance, no annual savings figure and no list of programs affected.
A late-stage trial still pending
The filing's emphasis on the preclinical pipeline sits against a clinical portfolio that its annual report, filed February 26, 2025, describes in two parts: latozinemab (AL001) and AL101/GSK4527226. Both aim to raise progranulin, a protein that regulates lysosomal function, neuronal survival and inflammation in the brain.
Latozinemab is being studied in INFRONT-3, a global, pivotal, 96-week Phase 3 trial in frontotemporal dementia with a granulin gene mutation (FTD-GRN). Enrollment was completed in October 2023, and the company said topline data were anticipated by the fourth quarter of 2025. The company says no therapies are approved for any form of frontotemporal dementia. In earlier studies it reported elevation of progranulin to the normal range and early signals of exploratory biomarker and clinical activity, which are not proof that the drug slows the disease. The FDA granted it Breakthrough Therapy Designation in February 2024, a status that does not change the standards for approval.
AL101/GSK4527226 is being co-developed with GSK for early Alzheimer's disease in PROGRESS-AD, a global, 76-week Phase 2 trial that began dosing in February 2024 and has a target enrollment of 282 participants. Alector and GSK planned to finish enrollment by mid-2025. Under a May 2023 amendment to their agreement, Alector is responsible for funding both companies' development costs, up to $140.5 million, for the initial Phase 2 trial. The company reported that in a separate Phase 2 trial, INVOKE-2, MRI findings resembling ARIA occurred, with a small number of serious adverse events, and that it stopped dosing and enrolling patients with the APOE e4/e4 genotype.
Debt
The annual report also describes a loan agreement with Hercules Capital, Inc., which acts as administrative agent and collateral agent for the lenders. It provides up to two tranches of term loans totaling up to $50,000,000. An initial $25.0 million tranche is available through June 30, 2026, and Alector borrowed $10.0 million at closing. A further $25.0 million tranche is at the lenders' sole discretion. Alector granted the collateral agent a first priority security interest on substantially all of its assets. The agreement contains covenants limiting asset disposals, certain licensing arrangements, mergers, additional debt and dividends, and a breach could lead to an event of default and acceleration.
Alector's preclinical programs include candidates built on its Alector Brain Carrier technology, which is meant to move drugs across the blood-brain barrier.